Comparative Pharmacology
Head-to-head clinical analysis: CALAN SR versus CARDENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALAN SR versus CARDENE.
CALAN SR vs CARDENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.
Oral: 180–240 mg once daily; maximum 480 mg/day.
20-40 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours (average ~8 hours) after single oral dose; may increase to 12-16 hours with chronic dosing due to saturable hepatic metabolism; clinical context: requires dosing adjustments in hepatic impairment.
1.5-2 hours (terminal); prolonged in hepatic impairment (up to 6-8 hours)
Approximately 70% of the dose is excreted as metabolites in the urine; 3-4% as unchanged drug; 25% eliminated in feces via biliary excretion.
Renal: 60% as metabolites, 10% unchanged; Fecal: 35%
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker